BusinessAchillion Reports First Quarter 2018 Financial Results and Management TransitionBy Nasdaq OMXMay 2, 2018, 10:35 AM UTC
BusinessAchillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 GlomerulopathyBy Nasdaq OMXFeb 26, 2018, 11:05 AM UTC
BusinessAchillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial ResultsBy Nasdaq OMXFeb 22, 2018, 11:05 AM UTC
BusinessAchillion to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceBy Nasdaq OMXFeb 9, 2018, 11:05 AM UTC
BusinessAchillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor DBy Nasdaq OMXDec 20, 2017, 11:05 AM UTC
BusinessAchillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical ProgramsBy Nasdaq OMXNov 1, 2017, 8:06 PM UTC
BusinessUSPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D InhibitorBy Nasdaq OMXOct 24, 2017, 10:05 AM UTC
